Phase IV clinical trials are one the fastest growing areas of clinical research. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which proves efficacy, safety and quality. Furthermore, a key driver is the demands of health technology assessors and payers and their need for evidence-based economic data, again over the long-term. However, as post-marketing studies tend to be more commercial in nature, successfully planning and implementing them can be a major challenge, especially in terms of motivating investigators and recruiting patients who may already have access to the latest medications.
The event will provide the latest and most valuable, real-life experiences in post-marketing studies, their benefits and challenges. It will be an ideal opportunity for benchmarking and networking with the experts.
Why attend?
- Gain access to the latest methodologies and real-life cases in the field
- Explore how market leaders are improving data accuracy
- Balancing conflicting scientific, regulatory & marketing needs
- Learn more about comparative studies and their value for drug safety
- Understand how key figures are affecting future trends and standards
- Understand regulatory / ethical priorities
- Find out how phase IV studies & observational research are being outsourced and how industry players are selecting the right partners
Visitors profilePharmaceutical & Biotech companies Vice Presidents, Directors & Managers of: Medical Affairs, Epidemiology, Clinical Development & Operations, Drug Safety, Pharmacovigilance, Data Management, Regulatory Affairs, Clinical Outsourcing
Relevant KeywordsClinical, Epidemiology, Clinical Outsourcing, Medical, Drug Safety, Pharmacovigilance, Data Management, Regulatory Affairs
